Lilly's Kisunla™ (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's Disease
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St rises on AI gains as oil slides, Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips briefly below $100 on Saudi exports, hopes of US-Iran diplomacy
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
BMO Capital Reiterates Outperform Rating on Eli Lilly (LLY)
July 2, 2024 3:04 PM EDTBMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $1,001.00 price target on Eli Lilly (NYSE: LLY).
The analyst comments "Approval of donanemab (branded Kisunla) is likely to expand revenue for both Lilly and Biogen/Eisai as two players are needed to grow infrastructure.... More
Morgan Stanley on Eli Lilly (LLY): 'we expect LLY shares to trade flat to slightly up'
July 2, 2024 2:41 PM EDTMorgan Stanley analyst Terence Flynn reiterated an Overweight rating and $1,023.00 price target on Eli Lilly (NYSE: LLY)
The analyst comments "The approval was in line with our expectations and we expect LLY shares to trade flat to slightly up as a result. For... More
